For COVID-19 Prevention and Treatment


Important Updates:

Clinical trial by Gautret, Raoult, et al. (2020)

Correspondence from Dr. Vladimir Zelenko in the successful treatment of COVID-19 patients with hydroxychloroquine and azithromycin

These Drugs Are Helping Our Coronavirus Patients (Wall Street Journal coverage of Dr. Jeff Colyer and Dr. Daniel Hinthorn on HCQ and AZ in treatment of novel coronavirus)

Letter to President Donald J. Trump from the Association of American Physicians and Surgeons

Coronavirus: The end of the Crisis? by the New York State Bar Association Environmental Law Section


What is this initiative?

This is an open-data repository for using hydroxychloroquine (HCQ) and azithromycin for both treatment and prevention of COVID-19, launched by an independent group of scientists, physicians, statisticians and lawyers.

Previous researches from France, South Korea and China demonstrated strong efficacy of HCQ against COVID-19. While undoubtedly pioneering and insightful, we acknowledge their limitations too - such as relatively small sample size.

This data repository differentiates from other HCQ studies and trial of other drugs, in a few key aspects:

  1. Evaluation of Prevention  (esp. in protecting healthcare workers)

The biggest systemic risk we face is our healthcare system becoming overwhelmed. If our PPE supplies are depleted, intensive care units overfilled and healthcare workers infected, mortality rates will rise sharply.

Our data hub focuses on prevention evaluation, as well as treatment. We think addressing both is the best way to "super flatten" the curve.

2. An "Open Source" Real-Time Data Hub

Time is of essence in this pandemic. Aggregating data from a network of  thousands (and growing) of MDs, allow it to scale to substantial number of patient data quickly.

The full data-set will be available and constantly updated to the public, as close to real-time as possible [1]. Any doctor, researcher or data scientist could then analyze, verify and extrapolate new insights for their prevention and treatment strategy.

3. Focus on affordable & accessible drug

HCQ is a long-time generic drug, extremely affordable and can be manufactured by any quality firm. No patent. No special interests.

[1] Data are vetted and collected only from medical professionals , and only in de-identified form.


Join the evaluation

  • Objective: Evaluate the efficacy of hydroxychloroquine (HCQ) in the prevention of COVID-19 infection.
  • Current Phase: We're initially focusing on a cohort of healthy medical professionals and healthcare workers.
  • Status: Active / Recruiting

If you're a front-line healthcare worker (physician, nurse, etc.), please send us an email. We need your participation—no matter if you plan to take HCQ or not (extremely valuable and necessary for comparison).

As our way of saying thank you for joining this initiative, all contributors will have the option to be publicly recognized in any publications.

Future phase: Case-control study of hydroxychloroquine in the prevention of COVID-19. Stay tuned.

Can my company / organization participate in this initiative?

We'd be happy to discuss.

Could I support the project in other ways?

If you're interested to support or partner on regulatory, clinical trial or funding, please send us an email.


Background

Read our landmark paper on the treatment of COVID-19 (March 13, 2020).

A recent controlled clinical study conducted by Didier Raoult MD/PhD, et al. in France has shown that 100% patients who received a combination of hydroxychloroquine and azithromycin tested negative and were virologically cured within 6 days of treatment.

In addition, recent guidelines from South Korea and China report that hydroxychloroquine and chloroquine are effective antiviral therapeutic treatments for novel coronavirus.

A therapeutic agent that prevents infection with novel coronavirus is highly desirable—especially for persons with high-risk exposure (e.g healthcare professionals) as well as persons with comorbidities (heart disease, diabetes, etc.) and compromised immune systems. Ground-breaking in vitro studies demonstrate potential efficacy of hydroxychloroquine as a prophylactic for novel coronavirus infection in primate cells.

Note: Hydroxychloroquine (brand name Plaquenil) is an inexpensive, globally available drug (tablet) that was approved for widespread medical use since 1955. It is commonly used today to treat malaria, systemic lupus erythematosus and rheumatoid arthritis.

NOT MEDICAL ADVICE. APPROPRIATE MEDICAL PROFESSIONALS MUST BE CONSULTED FOR EACH SPECIFIC SITUATION.


Project Lead

Gregory J. Rigano, Esq

Mr. Rigano led a biotech firm for the past five years in research and clinical evaluation of chloroquine in various diseases. He has provided counsel to over $1 billion in transaction volume at global scale with a strong focus on the sciences involving multi-national corporations and the federal government. Mr. Rigano’s experience includes advancing various pharmaceutical assets through laboratory, animal, formulation, manufacturing, clinical trials (Phase I - III) as well as commercialization. Mr. Rigano received his Juris Doctor degree from Hofstra University, and studied at Johns Hopkins University.

Consulting Scientists & Physicians

Didier Raoult​, MD & PhD

Didier Raoult created the Rickettsia Unit at Aix-Marseille University. Since 2008, Dr. Raoult has served as the director of URMITE (Research Unit in Infectious and Tropical Emergent Diseases), collaborating with CNRS (National Center for the Scientific Research), IRD (Research for the Development Institute), INSERM (National Institute of Health and Medical Research) and Aix Marseille University. His laboratory employs more than 200 people, including nearly 100 active researchers who publish between 250 and 350 papers per year and have produced over 50 patents.

Chandra Duggirala, MD

Chandra is a physician, clinical investigator, inventor and serial entrepreneur.

Actively treating patients in the hospital, ER and ICU, Chandra is diligently working to find prophylactic drugs for high risk health care workers. Chandra is focused on alleviating and eliminating the COVID-19 pandemic by using therapeutic, prophylactic and system design approaches to reduce the burden on our healthcare system and reduce morbidity and mortality caused by SARS-COV2.

Previously, he founded Novobionics, a medical device company to treat diabetes and obesity non-invasively and invented its double sleeve technology. He led the company through preclinical trials as well as securing several US and international patents. He serves as the Principal Investigator of the Reset-Youth trial, one of the largest clinical trials for investigating the reversibility of epigenetic markers of aging. He also founded a software company at the intersection of nutritional biology and A.I.


Disclaimer: This page is intended as reference for medical professionals only. The parties involved with covidtrial.io do not make and expressly disclaim all representations and warranties, express, implied, statutory or otherwise, whatsoever, including, but not limited to: (i) warranties of merchantability, fitness for a particular purpose, suitability, usage, title or noninfringement; (ii) that the contents are free from error; and (iii) that such contents will not infringe third-party rights. The parties shall have no liability for damages of any kind arising out of the use, reference to, or reliance on this page or any of the content contained herein, even if advised of the possibility of such damages. In no event will covidtrial.io and or its affiliates be liable to any person or entity for any damages, losses, liabilities, costs or expenses of any kind, whether direct or indirect, consequential, compensatory, incidental, actual, exemplary, punitive or special for the use of, reference to, or reliance on this white paper or any of the content contained herein, including, without limitation, any loss of business, revenues, profits, data, use, goodwill or other intangible losses.

Copyright. All Rights Reserved.